1ygc: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 1: Line 1:
[[Image:1ygc.gif|left|200px]]
{{Seed}}
[[Image:1ygc.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1ygc|  PDB=1ygc  |  SCENE=  }}  
{{STRUCTURE_1ygc|  PDB=1ygc  |  SCENE=  }}  


'''Short Factor VIIa with a small molecule inhibitor'''
===Short Factor VIIa with a small molecule inhibitor===




==Overview==
<!--
The serine protease factor VIIa (FVIIa) in complex with its cellular cofactor tissue factor (TF) initiates the blood coagulation reactions. TF.FVIIa is also implicated in thrombosis-related disorders and constitutes an appealing therapeutic target for treatment of cardiovascular diseases. To this end, we generated the FVIIa active site inhibitor G17905, which displayed great potency toward TF.FVIIa (Ki = 0.35 +/- 0.11 nM). G17905 did not appreciably inhibit 12 of the 14 examined trypsin-like serine proteases, consistent with its TF.FVIIa-specific activity in clotting assays. The crystal structure of the FVIIa.G17905 complex provides insight into the molecular basis of the high selectivity. It shows that, compared with other serine proteases, FVIIa is uniquely equipped to accommodate conformational disturbances in the Gln217-Gly219 region caused by the ortho-hydroxy group of the inhibitor's aminobenzamidine moiety located in the S1 recognition pocket. Moreover, the structure revealed a novel, nonstandard conformation of FVIIa active site in the region of the oxyanion hole, a "flipped" Lys192-Gly193 peptide bond. Macromolecular substrate activation assays demonstrated that G17905 is a noncompetitive, slow-binding inhibitor. Nevertheless, G17905 effectively inhibited thrombus formation in a baboon arterio-venous shunt model, reducing platelet and fibrin deposition by approximately 70% at 0.4 mg/kg + 0.1 mg/kg/min infusion. Therefore, the in vitro potency of G17905, characterized by slow binding kinetics, correlated with efficacious antithrombotic activity in vivo.
The line below this paragraph, {{ABSTRACT_PUBMED_15632123}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 15632123 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_15632123}}


==Disease==
==Disease==
Line 37: Line 41:
[[Category: Robarge, K.]]
[[Category: Robarge, K.]]
[[Category: Inverted oxy-anion hole]]
[[Category: Inverted oxy-anion hole]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 16:17:02 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 12:32:09 2008''

Revision as of 12:32, 29 July 2008

File:1ygc.png

Template:STRUCTURE 1ygc

Short Factor VIIa with a small molecule inhibitorShort Factor VIIa with a small molecule inhibitor

Template:ABSTRACT PUBMED 15632123

DiseaseDisease

Known disease associated with this structure: Factor VII deficiency OMIM:[227500], Myocardial infarction, decreased susceptibility to OMIM:[227500]

About this StructureAbout this Structure

1YGC is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo., Olivero AG, Eigenbrot C, Goldsmith R, Robarge K, Artis DR, Flygare J, Rawson T, Sutherlin DP, Kadkhodayan S, Beresini M, Elliott LO, DeGuzman GG, Banner DW, Ultsch M, Marzec U, Hanson SR, Refino C, Bunting S, Kirchhofer D, J Biol Chem. 2005 Mar 11;280(10):9160-9. Epub 2005 Jan 4. PMID:15632123

Page seeded by OCA on Tue Jul 29 12:32:09 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=1ygc&oldid=741310"